Genesis MedTech Group has officially unveiled its state-of-the-art medtech campus in Wuxi city, Jiangsu province, China.

Representing the first major R&D and manufacturing facility of its kind in China, it spans 135,333 sqm and has completed its first phase of development, featuring an innovation centre, and two R&D and production centres.

The Innovation Centre provides an open educational platform to foster deeper engagement and interaction between Genesis MedTech and medical professionals. It provides medical professionals access to clinical training of the latest medtech innovations, covering multiple disease fields, such as minimally invasive surgery, vascular interventions and structural heart disease.

Wuxi Campus of Genesis MedTech (Phase 1 Project)

The training facilities within the Innovation Centre provide the highest level of education and hands-on experience, recreating real-life clinical situations for healthcare practitioners to understand and familiarise themselves with cutting-edge medical devices.

Warren Wang, Chairman and CEO of Genesis MedTech
We are trying to play an integral role in MedTech innovation that will revolutionise how medtech development is intimately integrated with the practical needs of medical professionals. Through training and exchanges, we can better understand clinical needs, stimulate technological innovation and expand product development. The Campus will be an ultramodern nexus for R&D, manufacturing, training and exchange, providing our R&D teams and global experts with an open platform to explore innovations from ground zero, becoming an exploration and production centre for new technologies and products.

The Campus also houses the R&D and Manufacturing Centre, which develops and manufactures high-quality medical devices, focusing on cutting-edge medtech devices for minimally invasive surgery and vascular interventions. Pilot manufacturing commenced in September 2022 and is scheduled for full-scale production by the first half of 2023. It is expected to reach industrial-scale production levels with an output value of over 10 billion RMB (approximately US$1.38 billion) in three to five years.